RAC Charts, page-129

Makes for interesting analysis ... was trying to figure out why the apportionment in the recent CR was as it was ... basically it appears to be a "catch up" for Dr Cullity given Dr Tillet was offered 8.5m ... DrT had started buying on market prior, around 5c, and had accumulated 200k before the CR.

DrC will likely be the conduit for discussion with pharmas in the US I expect - that's his background.

I don't want to make any outlandish statements here - so think about this strategically from an Exec perspective relative to share holder value and forthcoming responsibility.

Interesting.

It also suggests DrT was building a position and decided there might be a quicker way to achieve that.

That's the strategy ... but timing is also significant ... the 9.9c options seemed short termed from my perspective. Aug 2021 expiry.

In perspective - there are 49c, 65c, 30c and 45c opts expiring 2019/2020, and a heap of 25c ones expiring July 2021.

So to have 9.9's expiring Aug 2021 suggests they expect them to be in the money IMO ... as a standby for funds and/or reward for this CR.

If you consider who has the 25's expiring July 2021 and who benefits from these new 9.9's expiring Aug 2021 ... it's interesting to say the least.